摘要
【目的】探讨切除修复交叉互补基因1（ERCC1）、蛋白激酶B（protein kinase B，PKB/AKT）两种蛋白在胃癌组织中表达情况及其意义。【方法】采用 SP免疫组织化学法检测76例胃癌组织中 ERCC1、AKT2蛋白的表达情况，并与42例正常胃黏膜组织进行比较。【结果】胃癌组织中 ERCC1、AKT2蛋白表达定位于细胞核和浆， ERCC1表达明显低于正常胃黏膜组织，而 AKT2阳性表达明显高于正常胃黏膜组织（P ＜0．05）。ERCC1和AKT2蛋白的表达与淋巴结转移及病理分期有关（P＜0．05），两者之间表达呈无明显相关性。术后化疗患者中ERCC1和 AKT2阴性者预后好于均阳性者。【结论】ERCC1和 AKT2在与胃癌预后及耐药密切相关，对其变化进行检测可帮助了解胃癌患者的肿瘤恶性程度，指导制定个体化治疗方案并判断预后。
[Obj ective]To explore the expression of excision repair cross complementing 1 （ERCC1 ）and pro-tein kinase B（AKT2）in gastric carcinoma and its significance.[Methods]The expressions of ERCC1 and AKT2 in 76 cases of gastric carcinoma tissues were detected by using SP immunohistochemical method,and compared with those in 42 cases of normal gastric mucosa tissues.[Results]The expression of ERCC1 and AKT2 in gastric carcinoma tissue was located in nucleus and plasma.The positive expression of ERCC1 in gastric carcinoma tissue was obviously lower than that in normal gastric mucosa tissue,while the positive expression of AKT2 in gastric carcinoma tissue was obviously higher than that in normal gastric mucosa tissue（P〈0.05）.The expressions of ERCC1 and AKT2 were related with lymph node metastasis and pathological stage（P〈0.05）.There was no ob-vious correlation between the expression of ERCC1 and AKR2.The prognosis of patients receiving postoperative chemotherapy with negative expression of ERCC1 and AKT2 was better than that of patients with positive expres-sion of ERCC1 and AKT2.[Conclusion]ERCC1 and AKT2 are closely related with the prognosis and resistance of gastric carcinoma.The detection of the changes of ERCC1 and AKT2 is helpful to understand malignant degree of patients with gastric cancer,instruct the setting of individualized treatment protocol and assess the prognosis.
出处
《医学临床研究》
CAS
2014年第5期972-974,共3页
Journal of Clinical Research
